BioSight
Companies
Syndax Pharmaceuticals Inc logo

SNDX

NASDAQNEW YORK, NY
Syndax Pharmaceuticals Inc

Syndax develops drugs targeting cancer and fibrotic diseases using modalities including histone deacetylase (HDAC) inhibitors. The company has two marketed products—REVUFORJ (revumenib) and NIKTIMVO (axatilimab-csfr)—and is advancing additional product candidates through clinical trials and preclinical studies. Syndax operates through licensed technology from partners including UCB Biopharma and Vitae Pharmaceuticals, and collaborates with Incyte Corporation on the development and commercialization of axatilimab.

Price history not yet available for SNDX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar